About
Our Corporate Mission
Saving lives and providing relief by tackling illnesses
BTB Therapeutics endeavors to create a more harmonious society by tackling illnesses and saving lives.
Message from CEO
Our company aims to develop drugs in a manner that differs starkly from existing venture companies. We are involved in drug development projects that swiftly utilize the results of core academic research performed mainly at Kyoto University to create drugs that are of practical value in medical care.
Specifically, we utilize the results of cutting-edge core research performed in academia to create clear target product profiles (TPP), develop optimal strategies for R&D, intellectual property, and pharmaceutical regulations so as to cross the Devil's River of drug development. We then formulate optimal development plans, raise adequate funding, and provide superior project management to bridge the Valley of Death of drug development. Finally, we overcome the Darwinian Sea of drug development by developing thoughtful business strategies based on the business portfolio and focus on business development. Our company hopes to play a part in making new drugs available to patients suffering from intractable diseases as quickly as possible.
We will take advantage of online technologies to provide development-related consultation for on-demand drug development with our team of experts, and actively cater to requests pertaining to the launch of spin-out venture companies and divestitures.
CEO
Takashi Kiyoizumi
Brief CV
| 1981 | Graduated from Keio University School of Medicine (Medical doctor) |
| 1989 | Completed Ph.D. at the Graduated from Keio University School of Medicine (Doctor of Medicine） |
| 1991 | Completed the Master's Program at the Sloan School of Management, Massachusetts Institute of Technology (Master of Business Administration) |
| June 1991 | ImmuLogic Pharmaceutical Corporation, Manager |
| March 1994 | Interneuron Pharmaceuticals Inc. Executive Director |
| May 1995 | Interneuron Pharmaceuticals Inc. Vice President |
| January 1998 | Interneuron Pharmaceuticals Inc. Senior Vice President |
| March 2000 | Tanabe Research Laboratories, USA, President and CEO |
| September 2000 | MediciNova Inc. President and CEO |
| November 2013 | Kiyoizumi Advisory LLC, Managing Director (Founded~present: concurrent appointment) |
| Other concurrent appointments | BioPacific Investors, Founding Member and Investor Japan Forum for Innovation and Technology, UC San Diego, Executive Manager Life Science Innovation Network in Japan (LINK-J), Supporter Thrive Bioscience, Executive Vice President of International NuFund Venture Group（former name : Tech Coast Angels-San Diego）, Member and Investor |
Director
Tsuyoshi Ogiku
Brief CV
| March 1983 | Completed the Master's Program at the Graduate School of Science, Osaka University |
| April 1983 | Joined Tanabe Pharma Corporation (currently Mitsubishi Tanabe Pharma Corporation) as a medicinal chemist |
| December 1992 | Graduated from the Graduate School of Science, Osaka University (Doctor of Science) |
| April 2010 | General Manager of Medicinal Chemistry Laboratories(1) |
| April 2013 | General Manager of the Exploratory Screening Center |
| July 2015 | General Manager of Research Core Units |
| October 2015 | Deputy Director of R & D Division |
| September 2016 | Specially-appointed Professor at the Graduate School of Medicine, Kyoto University |
| April 2018 | Director of Medical Development, Center for Clinical Research, Kyoto University Hospital (now Institute for Advancement of Clinical and Transitional Science (iACT)) |
| April 2023 | Deputy Director-General, Kyoto University Medical Science and Business Liaison Organization (present post) |
Non-executive Director
Masatoshi Hagiwara
Brief CV
| March 1988 | Completed Ph.D. at the Graduate School of Medicine, Mie University (Doctor of Medicine) |
| April 1988 | Teaching Assistant at the Department of Pharmacology, School of Medicine, Nagoya University |
| October 1993 | Lecturer at the Department of Anatomy and Cell Biology (Group 3), School of Medicine, Nagoya University |
| July 1995 | Assistant Professor at the Department of Anatomy and Cell Biology (Group 3), School of Medicine, Nagoya University |
| January 1997 | Professor at the Medical Research Institute, Tokyo Medical and Dental University |
| April 2003 | Professor at the School of Biomedical Science, Tokyo Medical and Dental University |
| July 2010 | Professor at the Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University |
| November 2011 | Founded the Medical Research Support Center at Kyoto University, and serving as its Director (current appointment) |
| April 2024 | Specially-appointed Professor at the Department of Drug Discovery Medicine, Graduate School of Medicine, Kyoto University (current appointment) |
Non-executive Director & Head of Licensing Operations
Tetsuharu Nagamoto
Brief CV
| Graduated from the School of Medicine, Kyoto University (Medical doctor) | |
| April 2005 | Research Assistant at the Trade Policy Unit, Economic & Social Policy Department, Policy Research Division, UFJ Research Institute |
| April 2008 | Consultant at the Life Sciences Unit, Deloitte Tohmatsu Consulting, LLC. |
| April 2012 | Resident & Advisor to the Clinical Trials Steering Committee at the Nanbu Medical Center / Nanbu Child Medical Center |
| April 2014 | Pediatrician at the Yokosuka General Hospital Uwamachi |
| May 2016 | Senior Principal at the Health & Public Services Division, Accenture |
| June 2017 | CHARTAE Consulting, LLC. (Founded~present: concurrent appointment) |
| Other concurrent appointments | Researcher at the Department of Systems Science, Graduate School of Informatics, Kyoto University Researcher at the Department of Materials Process Engineering, Graduate School of Engineering, Nagoya University Part-time Lecturer at the Faculty of Advanced Techno-Surgery, Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University Part-time Faculty Member at the Division of Intelligent Systems Engineering, Graduate School of Engineering, Yokohama National University |
Company Profile
| Company name | BTB Therapeutics Co.,Ltd. |
| Representative | Takashi Kiyoizumi |
| Founded | June 29th, 2020 |
| Capital | 57 million yen |
| Headquarters | 〒606-8507 Medical Innovation Center 4F, 53 Shogoin Kawahara-cho, Sakyo-ku, Kyoto E-mail: info@btb-newdrug.co.jp |